The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Absolute Neutrophil Cell (ANC) Engraftment
Timeframe: Day 100 Post-Procedure
Number of Participants with Platelet Engraftment
Timeframe: Day 100 Post-Procedure